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Abstract 
Purpose: To report the cases of two patients with chronic hepatitis C infection showing 
serous retinal detachments similar to Vogt-Koyanagi-Harada (VKH) disease.  
Methods: We reviewed the clinical records of two patients who were diagnosed with 
VKH-like disease during combined interferon-α (IFNα) and ribavirin treatment.  
Results: Interruption of IFNα and ribavirin treatment in association with oral 
corticosteroids resulted in a favorable visual outcome in the case of diffuse retinal 
detachment (case 1). On the contrary, visual acuity did not improve when late cicatricial 
stage disease was already present (case 2).  
Conclusion: There is increasing evidence of a link between hepatitis C virus infection 
treated with pegylated IFNα-2b and the development of VKH-like disease. Knowing the 
potential side effects of IFNα and ribavirin administration is fundamentally important, as 
is the need to closely follow up those patients that need to undergo this treatment. 
Introduction 
Vogt-Koyanagi-Harada (VKH) disease, also known as uveomeningitic syndrome, is a 
rare idiopathic multisystem autoimmune granulomatous disorder affecting the eyes, 
meninges, auditory system and skin. The disease is thought to be due to an autoimmune 
Th1-mediated response to a melanocyte-associated antigen [1], but the initiation 
mechanism and development of the exact process remain poorly understood. 
Recent reports suggest a link between hepatitis C virus (HCV) infection and/or its 
treatment and the development of bilateral uveitis that is virtually identical to VKH  
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disease. We present two cases of VKH-like disease in patients treated with pegylated 
interferon-α (IFNα) and ribavirin for chronic hepatitis C. 
Case Report 
Case 1 
A 61-year-old woman contracted HCV in 2006 following a blood transfusion performed during a 
colectomy for adenocarcinoma. The patient’s past medical history was relevant only for type I diabetes 
mellitus controlled with insulin therapy. Because of histological damage at liver biopsy, she was 
prescribed pegylated IFNα and ribavirin treatment from October 2006. After 3 months, the patient was 
referred to a hepatologist because of sudden vision loss in both eyes. The physician suspected an 
interferon-related side effect and immediately interrupted the treatment. Upon presentation at our 
Ocular Immunology and Uveitis Service, the patient’s best-corrected visual acuity was hand motion in 
the right eye and 20/400 in the left eye. The anterior segment examination was normal and intraocular 
pressure was 10 mm Hg in both eyes. The fundus examination showed diffuse bilateral serous retinal 
detachment (fig. 1). No auditory or neurological symptoms were noted, nor vitiligo, alopecia, or 
poliosis. Based on the revised diagnostic criteria for VKH we diagnosed ‘probable’ VKH disease and 
prescribed treatment with oral prednisone 25 mg/die; the patient recovered to 20/25 in the right eye and 
to 20/20 in the left eye. 
Case 2 
A 36-year-old man with HCV since 2004 was taking pegylated IFNα and ribavirin during the same 
period. He also suffered from celiac disease. After 6 months of treatment, he referred bilateral sudden 
vision loss to his ophthalmologist and was treated with 12.5 mg oral prednisone per day without visual 
improvement. The patient was referred to our Ocular Immunology and Uveitis Service 15 months after 
the onset of initial symptoms for a second diagnostic and therapeutic opinion. At presentation, best-
corrected visual acuity was 20/200 in the right eye and 20/40 in the left eye. No neurological or auditory 
signs were noted, nor were vitiligo, poliosis or alopecia. The anterior segment revealed a marked 
posterior cortical cataract in the right eye and an initial posterior subcapsular cataract in the left eye. We 
noted bilateral nummular chorioretinal depigmented scars and retinal pigment epithelium clumping 
and migration compatible with late cicatricial stage probable VKH disease (fig. 2). Previous fluorescein 
angiograms showed multiple pinpoint hyperfluorescence at the level of the pigment epithelium and 
diffuse exudative retinal detachments in both eyes. Despite discontinuation of IFNα and ribavirin visual 
acuity did not improve. 
Discussion 
A causal effect between IFNα treatment for HCV infection and VKH disease has not 
yet been proven. The exact etiology of VKH itself remains unclear. VKH syndrome is 
possibly caused by a T cell-mediated autoimmune reaction against proteins related with 
choroidal melanocytes. The fact that the disease prevalence varies considerably among 
populations and that it commonly affects people with more pigmented skin and a certain 
HLA (human leukocyte antigen) predisposition highlights the importance of individual 
genetic predisposition for the development of VKH disease. However, the autoimmune 
reaction needs to be initiated by a triggering agent. Epstein-Barr or cytomegalovirus 
infections have been proposed as initiating factors. The infection may lead to the 
production of autoreactive antibodies through a process of molecular mimicry between 
viral and melanocyte-related antigens [1].  
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The immunogenicity of IFNα in ocular tissue has been known since 1997 when a 
possible role in the development of Behçet’s disease, another autoimmune disorder in 
which T cell-mediated activation is thought to play a major role, was suggested. 
Furthermore, interferon and ribavirin can induce a Th1 response and modify the 
expression of MHC class II antigens, both of which are associated with the development 
of VKH disease. Therefore, despite the lack of evidence of a causal effect, IFNα and 
ribavirin might be involved in both the initiation of the autoimmune process and the 
induction of a higher susceptibility in developing VKH syndrome. The association 
between VKH-like syndrome and interferon treatment for hepatitis C was first suggested 
in 2003 [2]. Since then, seven other cases of HCV-positive patients presenting a VKH-like 
disease after IFNα treatment have been reported in the literature [3–5]. Most of the 
reported cases (table 1) show signs of systemic involvement such as skin lesions, auditory 
or neurologic symptoms in association with serous retinal detachment, which is one of 
the hallmarks of VKH disease. Nevertheless, our cases highlight the importance of 
including serous retinal detachment without systemic signs in suspecting VKH-like 
disease in patients under IFNα and ribavirin treatment for hepatitis C. 
Despite the widespread use of interferon and ribavirin for the treatment of hepatitis C, 
the small number of published cases of VKH-like disease following IFNα treatment shows 
that ocular immunological side effects are rare. However, IFNα may cause other more 
common significant side effects, including retinal vascular disorders, ischemic optic 
neuropathies, neovascular glaucoma and ‘specific IFNα-related retinopathy,’ i.e. 
retinopathy characterized by retinal hemorrhages, microaneurysms, and cotton-wool 
spots. 
The presented cases emphasize the importance of early recognition and prompt 
adequate ophthalmological therapy in the presence of a VKH-like disease associated with 
IFN treatment. Discontinuation of IFN and ribavirin treatment in association with oral 
corticosteroids might result in a favorable visual outcome in the case of diffuse retinal 
detachment (case 1). Conversely, visual recovery is usually poor when late cicatricial stage 
disease is already present (case 2). If not promptly recognized, IFNα-related effects may 
lead to chronic bilateral severe vision loss. Therefore, it is of fundamental importance to 
recognize the potential side effects of IFNα and ribavirin administration, and to closely 
follow up patients if treatment needs to be continued.  
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Table 1. Comparison with previously reported cases of VKH-like disease associated with IFN treatment 
Case 
No. [ref.] 
Origin Age  Sex  VA  at   
presentation 
Anterior segment  Posterior segment  Systemic  
involvement 
VA at  
follow-up 
1 [2]  Latino  52  F  <20/200  posterior synechiae  vitritis, choroidal and scleral 
thickening (echography) 
AL, AU  HM 
2 [3]  Asian  36  M  NR  NR  serous retinal detachment, optic 
disk swelling 
HE 20/20 
3 [4]  Mediterranean  38  F  20/80 OD,  
20/200 OS 
mild anterior chamber 
reaction 
serous retinal detachment, optic 
disk swelling 
HE, AU, ME  20/20 and 
20/20 
4 [5]  Northern Europe  42  M  20/25 OD,  
20/40 OS 
normal  serous retinal detachment, 
choroidal folds, hyperemic optic 
disk 
VI, HE, PL  20/20 both 
eyes 
5 [5]  Northern Europe  43  F  20/200 OD,  
20/40 OS 
bilateral keratic  
precipitates; 1+ cells  
and flare 
serous retinal detachment  PO, VI, HE  20/20 both 
eyes 
6 [5]  Mediterranean  37  M  20/200 OD,  
HM OS 
normal  serous retinal detachment, optic 
disk swelling, vitritis 
PO, HE, AU, PL  20/20 OD, 
20/400 OS 
7 [5]  Northern Europe  52  F  20/200 OD,  
20/40 OS 
normal  serous retinal detachment, 
hyperemic optic disk 
AL, AU  20/20 both 
eyes 
8 Mediterranean  61  F  HM  OD,   
20/400 OS 
normal  serous retinal detachment  none  20/25 OD, 
20/20 OS 
9 Mediterranean  36  M  20/200  OD,   
20/40 OS 
posterior cortical  
cataract (OD),  
posterior subcapsular 
cataract (OS) 
chorioretinal scars and retinal 
pigment epithelium clumping 
none 20/200  OD, 
20/40 OS 
Cases 8 and 9 are from the present paper. VA = Visual acuity; NR = not reported; VI = vitiligo; PO = poliosis; AL = alopecia; HE = headache; 
ME = meningism; AU = auditory symptoms; PL = pleoxytosis; HM = hand motion; OD = right eye; OS = left eye. 
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Fig. 1. Fundus photography evidencing diffuse serous retinal detachment (left eye). 
 
 
 
Fig. 2. Posterior pole photography evidencing depigmented scars and retinal pigment epithelium 
clumping (left eye). 
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